# Article information:

HDAC inhibition potentiates immunotherapy in triple negative breast cancer - PMC  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768393/>

# Article summary:

1. Triple-negative breast cancer (TNBC) is a difficult subtype of breast cancer with poor prognosis and high risk of relapse.

2. Histone deacetylase inhibitors (HDACi) can up-regulate PD-L1 expression in TNBC cells, making them more susceptible to immunotherapy.

3. The combination of HDACi and immune checkpoint inhibitors can significantly enhance the response to immunotherapy in TNBC, leading to decreased tumor growth and increased survival.

# Article rating:

Appears strongly imbalanced: The article is written in a biased or one-sided way, and the information it provides is not trustworthy enough to be considered a reliable source. You should consult other sources to find reliable information on the presented issues.

# Article analysis:

该文章是一篇研究性质的论文，旨在探讨组蛋白去乙酰化酶抑制剂（HDACi）与免疫检查点抑制剂联合应用对三阴性乳腺癌（TNBC）治疗的潜在作用。然而，该文章存在以下问题：

1. 偏见来源：该文章没有明确提及作者的利益冲突声明，可能存在偏见来源。

2. 片面报道：该文章只关注了HDACi与免疫检查点抑制剂联合应用对TNBC治疗的潜在作用，但并未探讨其他可能的治疗方案或其它类型的乳腺癌。

3. 无根据主张：该文章声称HDACi可以促进肿瘤抗原呈递和免疫细胞活化，但并未提供足够的证据支持这一主张。

4. 缺失考虑点：该文章没有考虑到HDACi可能会引起不良反应或毒性，并未探讨如何减轻这些风险。

5. 主张缺失证据：尽管该文章声称HDACi与免疫检查点抑制剂联合应用可以显著降低肿瘤生长并提高患者生存率，但并未提供足够的证据支持这一主张。

6. 未探索反驳：该文章没有探讨可能存在的反驳观点或其他治疗方案的优缺点。

7. 宣传内容：该文章可能存在宣传内容，试图推销HDACi与免疫检查点抑制剂联合应用作为TNBC治疗的最佳选择。

综上所述，该文章存在多个问题，读者需要谨慎对待其结论。

# Topics for further research:

* Conflict of interest statement
* Other treatment options for TNBC
* Evidence for HDACi promoting tumor antigen presentation and immune cell activation
* Potential adverse effects and toxicity of HDACi
* Evidence for HDACi and immune checkpoint inhibitor combination therapy in reducing tumor growth and improving patient survival
* Refuting viewpoints and comparison of treatment options

# Report location:

<https://www.fullpicture.app/item/7d7e6790ca46f8e589ba76261c4b7960>